
Gerhard Müller-Newen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2787739/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. Leukemia, 2022, 36, 333-347.	3.3	10
2	Phenotypic variability, not noise, accounts for most of the cell-to-cell heterogeneity in IFN-Î ³ and oncostatin M signaling responses. Science Signaling, 2022, 15, eabd9303.	1.6	20
3	Biofunctionalization of Dental Abutment Surfaces by Crosslinked ECM Proteins Strongly Enhances Adhesion and Proliferation of Gingival Fibroblasts. Advanced Healthcare Materials, 2021, 10, e2100132.	3.9	13
4	The Impact of Plasma-Derived Microvesicles From a Femoral Fracture Animal Model on Osteoblast Function. Shock, 2020, 53, 78-87.	1.0	2
5	Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers, 2020, 12, 3412.	1.7	3
6	Genetic barcoding reveals clonal dominance in iPSC-derived mesenchymal stromal cells. Stem Cell Research and Therapy, 2020, 11, 105.	2.4	13
7	Ribonuclease 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of polymicrobial sepsis. JCI Insight, 2020, 5, .	2.3	34
8	Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis. Kidney International, 2019, 96, 505-516.	2.6	35
9	Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia, 2019, 33, 1964-1977.	3.3	35
10	Nucleocytoplasmic Shuttling of STATs. A Target for Intervention?. Cancers, 2019, 11, 1815.	1.7	10
11	JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia, 2019, 33, 995-1010.	3.3	43
12	mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. JCI Insight, 2019, 4, .	2.3	69
13	Nucleolar-nucleoplasmic shuttling of TARG1 and its control by DNA damage-induced poly-ADP-ribosylation and by nucleolar transcription. Scientific Reports, 2018, 8, 6748.	1.6	32
14	Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism. Biology Open, 2018, 7, .	0.6	26
15	Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-In silico Approach Combining In vitro Experiments and Machine Learning. Frontiers in Immunology, 2018, 9, 393.	2.2	8
16	Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9282-9287.	3.3	68
17	Nuclear translocation of STAT3 and NF-ήB are independent of each other but NF-ήB supports expression and activation of STAT3. Cellular Signalling, 2017, 32, 36-47.	1.7	31
18	Development of platelets during steady state and inflammation. Journal of Leukocyte Biology, 2017, 101, 1109-1117	1.5	18

#	Article	IF	CITATIONS
19	Gli1 + Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell, 2017, 20, 785-800.e8.	5.2	195
20	Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nature Medicine, 2017, 23, 579-589.	15.2	571
21	Cellular Uptake: Assessing the Intracellular Integrity of Phosphine-Stabilized Ultrasmall Cytotoxic Gold Nanoparticles Enabled by Fluorescence Labeling (Adv. Healthcare Mater. 24/2016). Advanced Healthcare Materials, 2016, 5, 3088-3088.	3.9	0
22	The synthetic antimicrobial peptide 19-2.5 attenuates mitochondrial dysfunction in cardiomyocytes stimulated with human sepsis serum. Innate Immunity, 2016, 22, 612-619.	1.1	10
23	Assessing the Intracellular Integrity of Phosphineâ€Stabilized Ultrasmall Cytotoxic Gold Nanoparticles Enabled by Fluorescence Labeling. Advanced Healthcare Materials, 2016, 5, 3118-3128.	3.9	6
24	Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization. Scientific Reports, 2016, 6, 35454.	1.6	11
25	Dissecting functions of the N-terminal domain and GAS-site recognition in STAT3 nuclear trafficking. Cellular Signalling, 2016, 28, 810-825.	1.7	12
26	Proteolytic Cleavage Governs Interleukin-11 Trans-signaling. Cell Reports, 2016, 14, 1761-1773.	2.9	104
27	Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Scientific Reports, 2015, 5, 14685.	1.6	8
28	Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy. Journal of Hematology and Oncology, 2015, 8, 64.	6.9	23
29	Soluble Heparan Sulfate in Serum of Septic Shock Patients Induces Mitochondrial Dysfunction in Murine Cardiomyocytes. Shock, 2015, 44, 569-577.	1.0	32
30	MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAPâ€70 signaling, and lymphocyte chemotaxis. FASEB Journal, 2015, 29, 4497-4511.	0.2	129
31	Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction. Cell Communication and Signaling, 2015, 13, 10.	2.7	11
32	Consequences of the disease-related L78R mutation for dimerization and activity of STAT3. Journal of Cell Science, 2014, 127, 1899-910.	1.2	26
33	Gp130-dependent signaling in the podocyte. American Journal of Physiology - Renal Physiology, 2014, 307, F346-F355.	1.3	20
34	Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies. Cell Communication and Signaling, 2014, 12, 14.	2.7	13
35	Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms. Journal of Hematology and Oncology, 2014, 7, 92.	6.9	29
36	Arginine residues within the DNA binding domain of STAT3 promote intracellular shuttling and phosphorylation of STAT3. Cellular Signalling, 2014, 26, 1698-1706.	1.7	8

#	Article	IF	CITATIONS
37	Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling. Cancer Research, 2014, 74, 1227-1237.	0.4	169
38	Cellular uptake of fluorophore-labeled glyco-DNA–gold nanoparticles. Journal of Nanoparticle Research, 2013, 15, 1.	0.8	1
39	Mutations in the interleukin receptor <i><scp>IL</scp>11<scp>RA</scp></i> cause autosomal recessive Crouzonâ€like craniosynostosis. Molecular Genetics & Genomic Medicine, 2013, 1, 223-237.	0.6	70
40	Dominant-negative activity of the STAT3-Y705F mutant depends on the N-terminal domain. Cell Communication and Signaling, 2013, 11, 83.	2.7	24
41	Enterocytes Of Patients With Uncontrolled Acute Graft Versus Host Disease Of The Gut Undergo Massive Telomere Shortening Compared To Unaffected Controls. Blood, 2013, 122, 4467-4467.	0.6	0
42	Plasticity and cross-talk of Interleukin 6-type cytokines. Cytokine and Growth Factor Reviews, 2012, 23, 85-97.	3.2	311
43	Receptor fusion proteins for the inhibition of cytokines. European Journal of Cell Biology, 2012, 91, 428-434.	1.6	5
44	Dynamics and non-canonical aspects of JAK/STAT signalling. European Journal of Cell Biology, 2012, 91, 524-532.	1.6	80
45	Directed Covalent Immobilization of Fluorescently Labeled Cytokines. Bioconjugate Chemistry, 2011, 22, 1210-1220.	1.8	18
46	A receptor fusion protein for the inhibition of murine oncostatin M. BMC Biotechnology, 2011, 11, 3.	1.7	10
47	The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. Journal of Cell Science, 2011, 124, 900-909.	1.2	66
48	Splice Variants of the Dual Specificity Tyrosine Phosphorylation-regulated Kinase 4 (DYRK4) Differ in Their Subcellular Localization and Catalytic Activity*. Journal of Biological Chemistry, 2011, 286, 5494-5505.	1.6	41
49	Development of an IL-6 Inhibitor Based on the Functional Analysis of Murine IL-6Rα1. Chemistry and Biology, 2009, 16, 783-794.	6.2	11
50	Novel Inhibitors for Murine and Human Leukemia Inhibitory Factor Based on Fused Soluble Receptors. Journal of Biological Chemistry, 2008, 283, 5985-5995.	1.6	19
51	Nucleocytoplasmic shuttling of persistently activated STAT3. Journal of Cell Science, 2007, 120, 3249-3261.	1.2	89
52	Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP. Journal of Biological Chemistry, 2007, 282, 1238-1248.	1.6	20
53	Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. International Journal of Colorectal Disease, 2006, 21, 573-581.	1.0	9
54	Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. Journal of Cell Science, 2005, 118, 5129-5140.	1.2	74

#	Article	IF	CITATIONS
55	STAT3 is enriched in nuclear bodies. Journal of Cell Science, 2004, 117, 339-349.	1.2	58
56	Real Time Analysis of STAT3 Nucleocytoplasmic Shuttling. Journal of Biological Chemistry, 2004, 279, 15114-15123.	1.6	127
57	The Cytokine Receptor gp130: Faithfully Promiscuous. Science Signaling, 2003, 2003, pe40-pe40.	1.6	49
58	Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochemical Journal, 2003, 374, 1-20.	1.7	2,784
59	Long Term Association of the Cytokine Receptor gp130 and the Janus Kinase Jak1 Revealed by FRAP Analysis. Journal of Biological Chemistry, 2003, 278, 39205-39213.	1.6	46
60	A Fusion Protein of the gp130 and Interleukin-6Rα Ligand-binding Domains Acts as a Potent Interleukin-6 Inhibitor. Journal of Biological Chemistry, 2003, 278, 16968-16972.	1.6	33
61	Structural Bases of Receptor-JAK-STAT Interactions. , 2003, , 43-53.		Ο
62	Identification of the domain in the human interleukin-11 receptor that mediates ligand binding11Edited by J. A. Wells. Journal of Molecular Biology, 2001, 306, 263-274.	2.0	23
63	Two Different Epitopes of the Signal Transducer gp130 Sequentially Cooperate on IL-6-Induced Receptor Activation. Journal of Immunology, 2000, 165, 7042-7049.	0.4	39
64	Monoclonal antibodies against the human interleukin-11 receptor alpha-chain (IL-11Rα) and their use in studies of human mononuclear cells. Journal of Immunological Methods, 2000, 241, 43-59.	0.6	10
65	The Cytoplasmic Tyrosine Motifs in Full-Length Clycoprotein 130 Have Different Roles in IL-6 Signal Transduction. Journal of Immunology, 2000, 164, 848-854.	0.4	80
66	Importance of the Membrane-Proximal Extracellular Domains for Activation of the Signal Transducer Glycoprotein 130. Journal of Immunology, 2000, 164, 273-282.	0.4	67
67	Studies on the Interleukin-6-type Cytokine Signal Transducer gp130 Reveal a Novel Mechanism of Receptor Activation by Monoclonal Antibodies. Journal of Biological Chemistry, 2000, 275, 4579-4586.	1.6	37
68	Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factor. FEBS Letters, 2000, 468, 120-124.	1.3	21
69	A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Letters, 1999, 450, 117-122.	1.3	45
70	Constitutive internalization and association with adaptor protein-2 of the interleukin-6 signal transducer gp130. FEBS Letters, 1998, 441, 231-234.	1.3	41
71	Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemical Journal, 1998, 334, 297-314.	1.7	1,895
72	Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. Biochemical Journal, 1998, 331, 695-702.	1.7	77

#	Article	IF	CITATIONS
73	Molecular Modeling-guided Mutagenesis of the Extracellular Part of gp130 Leads to the Identification of Contact Sites in the Interleukin-6 (IL-6)·IL-6 receptor·gp130 Complex. Journal of Biological Chemistry, 1997, 272, 23748-23757.	1.6	68
74	Reconstitution of two isoforms of the human interleukin-11 receptor and comparison of their functional properties. FEBS Letters, 1997, 407, 141-147.	1.3	31
75	Soluble Human Interleukin-6 Receptor. Expression in Insect Cells, Purification and Characterization. FEBS Journal, 1995, 234, 661-669.	0.2	85
76	Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. European Journal of Immunology, 1995, 25, 3474-3481.	1.6	92